ExecutiveOrdersEO
EO 14297Executive OrderTrump 47 · R

Executive Order 14297

Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients

This executive order directs the Administration to pursue most-favored-nation prescription drug pricing, requiring pharmaceutical manufacturers to offer U.S. patients prices comparable to other developed nations or face potential rulemaking, importation waivers, antitrust enforcement, export reviews, and FDA approval modifications. It establishes a 30-day deadline for HHS to communicate price targets to drug makers, with escalating measures if progress is not achieved.

Federal Register Open PDF 90 FR 20749

Impact dates

  1. HHS Secretary communicates MFN price targets to pharmaceutical manufacturers

Market exposure

Policy exposure mapping — not investment advice. Illustrative public companies are incomplete and not recommendations.

Sectors

Pharma

Mechanisms

TariffBan / prohibitionLicensingProcurement

Role pressure

  • AdverseDomestic producer — Faces MFN price targets and potential rulemaking, importation competition, antitrust scrutiny, export restrictions, and FDA approval leverage if prices not reduced to international levels
  • MixedImporter — Potential new importation pathways via section 804(j) waivers create opportunity, but contingent on HHS certification and FDA action with uncertain timing
  • UncertainDownstream manufacturer — Precursor material export reviews (Sec. 5(b)(iv)) could constrain input access depending on scope of Commerce action
  • AdverseTrading-partner exporter — U.S. pressure to end 'freeloading' and Commerce/USTR action against foreign price suppression threatens existing pricing arrangements in developed nations

Geographies

USEUJPKRCAUKOTHER

Illustrative public companies

Curated watchlist matches by sector/role — incomplete; not a recommendation.

LLYEli LillyJNJJohnson & JohnsonMRKMerckNVSNovartisPFEPfizer

Confidence: medium · Policy alerts

Key directives

  • Secretary of Commerce and USTR to take action against foreign price suppression practices (Sec. 3)
  • HHS Secretary to facilitate direct-to-consumer purchasing programs at MFN prices (Sec. 4)
  • HHS Secretary to communicate MFN price targets to manufacturers within 30 days (Sec. 5(a))
  • If progress lacking: HHS to propose MFN pricing rulemaking (Sec. 5(b)(i))
  • If progress lacking: HHS to consider section 804(j) importation certification; FDA Commissioner to act on waivers if certified (Sec. 5(b)(ii))
  • If progress lacking: Attorney General and FTC to undertake antitrust enforcement based on EO 14273 report (Sec. 5(b)(iii))
  • If progress lacking: Commerce to review export actions on drugs/precursors (Sec. 5(b)(iv))
  • If progress lacking: FDA Commissioner to review/modify/revoke drug approvals (Sec. 5(b)(v))
  • Agency heads to take all available action to address global freeloading (Sec. 5(b)(vi))

Who is ordered

Timeline

Immediate

  • HHS to communicate most-favored-nation price targets to pharmaceutical manufacturers within 30 days
  • Commerce and USTR directed to address foreign price suppression practices

Near term (90d)

  • Potential rulemaking proposal for most-favored-nation pricing if progress lacking
  • HHS consideration of section 804(j) importation certification to Congress
  • FDA Commissioner action on importation waivers if Secretary certifies
  • Attorney General and FTC antitrust enforcement based on EO 14273 report findings
  • Commerce review of pharmaceutical/precursor export controls

Long term

  • Structural shift in U.S. pharmaceutical pricing toward international reference pricing
  • Potential modification or revocation of FDA drug approvals for unsafe/ineffective/improperly marketed drugs
  • Export restriction actions on drugs or precursor materials

Risks & tensions

  • Vague trigger for 'significant progress' in Sec. 5(b) creates implementation uncertainty
  • Section 804(j) importation certification has statutory prerequisites that may constrain action
  • FDA approval modification/revocation authority (Sec. 5(b)(v)) could face legal challenge if used for pricing leverage rather than safety/efficacy grounds
  • Antitrust enforcement tied to pending EO 14273 report creates sequential dependency
  • Export controls on precursor materials (Sec. 5(b)(iv)) could disrupt global supply chains and provoke retaliation
  • 'To the extent consistent with law' qualifiers throughout limit binding effect
Executive Order 14297: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients · Executive Orders